ANGLE plc

ANGLE plc Surrey Research Park 10 Nugent Road Guildford GU2 7AF‏United Kingdom u203aPINK (LSE) u256mEUR (ENTERED) n/an/a49-58GMT+1 https://angleplc.com

Biography:  https://finance.yahoo.com/quote/AGL.L/profile/

42%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a poor reputation for journalistic standards and is not considered a reliable news source.

Bias

50%

Examples:

  • The article mentions that ANGLE plc will be showcasing its Parsortix system at a leading European breast cancer conference. However, there are no references to any other company or organization hosting this event.
  • The article mentions that EBCC is focused on multidisciplinary, high-quality clinical and translational research with an emphasis on innovation and technology in managing breast cancer. However, it also states that the conference is attended by patient advocates and industry representatives providing sales, partnerships or collaborations opportunities.

Conflicts of Interest

0%

Examples:

Contradictions

85%

Examples:

  • Health chiefs hope the exciting scheme will help patients get targeted treatments quicker boosting their survival rates.
  • Thousands of Brits with suspected lung cancer will be offered a new blood test to detect the killer disease quicker as part of an NHS trial.

Deceptions

65%

Examples:

  • The article does not provide any information about the clinical trials or evidence for the effectiveness of Parsortix system in detecting breast cancer.
  • The article implies that ANGLE plc is a leader in developing cancer diagnostics products without providing any context or comparison with other companies or organizations.

Recent Articles

Revolutionizing Lung Cancer Detection: ctDNA Liquid Biopsies Provide Personalized Treatment Plans with Fewer Side Effects

Revolutionizing Lung Cancer Detection: ctDNA Liquid Biopsies Provide Personalized Treatment Plans with Fewer Side Effects

Broke On: Thursday, 21 March 2024 A new blood test called ctDNA liquid biopsies can detect lung cancer at an early stage and provide targeted treatments for patients. These tests look for tiny fragments of tumor DNA circulating in the bloodstream and allow doctors to make more accurate diagnoses, offer personalized treatment plans, and have fewer side effects than traditional chemotherapy.